ResMed (NYSE: RMD) is expected to report Q1 earnings on Oct. 25. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ResMed's revenues will increase 8.7% and EPS will increase 34.3%.

The average estimate for revenue is $342.0 million. On the bottom line, the average EPS estimate is $0.47.

Revenue details
 Last quarter, ResMed logged revenue of $371.9 million. GAAP reported sales were 8.8% higher than the prior-year quarter's $341.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.54. GAAP EPS of $0.53 for Q4 were 43% higher than the prior-year quarter's $0.37 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 60.9%, 210 basis points better than the prior-year quarter. Operating margin was 24.1%, 390 basis points better than the prior-year quarter. Net margin was 20.7%, 360 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $1.50 billion. The average EPS estimate is $2.04.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 182 members out of 196 rating the stock outperform, and 14 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 49 give ResMed a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $34.25.